The investigations center on whether these proposed deals unfairly privilege insiders or incorporate restrictive clauses that discourage superior competing bids. In the case of Theravance Biopharma, the firm is reviewing the company’s sale to Zymeworks at $17.00 per share. Similarly, the acquisition of Iridium Communications by Rocket Lab—a deal involving both cash and stock—is under review for its valuation and exchange structure.

Legal inquiries also target the merger between LCI Industries and Patrick Industries. While Patrick Industries shareholders are set to control approximately 52% of the combined entity, the equity-based nature of the deal has raised questions regarding long-term value for investors. Halper Sadeh representatives indicate they may seek increased consideration or additional public disclosures to ensure transparency. The firm handles such matters on a contingent fee basis, aiming to secure relief or corporate reforms for affected stakeholders across these four distinct transactions.